Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.80
-$0.11(-2.78%)
At close: 4:00 PM EST
$4.80
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$2.72 - $6.42
Previous CloseN/A
Volume147.46K
Average Volume (3M)2.70M
Market Cap
$384.37M
Enterprise Value$209.55
Total Cash (Recent Filing)$200.38M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding103,882,935
10 Day Avg. Volume2,093,759
30 Day Avg. Volume2,698,324
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside160.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress - Rolling BLAA rolling BLA submission with FDA alignment on a surrogate (skin frataxin) is a structural de-risking event: it shortens regulatory timelines, supports an accelerated approval pathway, and positions nomlabofusp to become a first-in-class disease-modifying therapy if confirmatory data follow, materially changing long-term commercial prospects.
Near-term Funding Runway After FinancingA $200.4M cash balance after a recent equity offering provides the company with tangible financing to advance pending BLA modules and initiate a global confirmatory Phase 3. This reduces immediate refinancing risk and enables execution on regulatory and clinical milestones over the next several quarters.
Low Financial LeverageMinimal debt limits fixed financial obligations and preserves flexibility to raise capital via equity or partnerships. For a pre-revenue biotech, low leverage lowers bankruptcy risk and supports strategic choices (e.g., partnering, milestone-based deals) without high interest burdens that could constrain R&D investment.
Bears Say
Pre-revenue With Materially Larger LossesOperating without product revenue means the company must rely on external capital; escalating net losses to -$166M TTM increase the quantum and frequency of required financings. Persistently negative earnings limit internal reinvestment capacity and make long-term sustainability contingent on successful development or partnerships.
Accelerating Cash Burn And Limited RunwayRising operating cash outflows (roughly -$131.3M TTM and accelerating year-over-year) create steady funding pressure. Even with current cash, the burn profile makes the company dependent on timely equity or deal-based financing, increasing execution risk and potential dilution over the medium term.
Increased Dilution Capacity From Authorized Share ExpansionApproval to nearly double authorized shares structurally increases the company's ability to issue equity for cash or deals. While providing financing flexibility, it raises the persistent risk of shareholder dilution across future financings, which can erode per-share economics and investor returns if capital is repeatedly sourced through new equity.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.71 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $384.37M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (160.42% Upside)
$12.50 (160.42% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 8.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $166.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Stock 12 Month Forecast
Average Price Target
$12.50
▲(160.42% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.99% Insiders
5.48% Mutual Funds
0.50% Other Institutional Investors
49.62% Public Companies and Individual Investors